Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Synlife logo — Artificial cells as novel therapeutics.

Synlife

Artificial cells as novel therapeutics.

Founded 2017 United States Cambridge, United States 3 employees Seed Total: $700.00K Biotechnology, Health Care +1

General Information

Company Name Synlife
Founded Year 2017
Location United States Cambridge, United States +1
Employees 3
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Social

Get notified when Synlife moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Synlife

Synlife is a biotechnology startup founded in 2017, with a focus on developing artificial cells for the treatment of metabolic diseases. Their slogan, "Artificial cells as novel therapeutics," encapsulates their innovative approach. In July 2018, they secured a $700.00K investment in a Seed Round, signaling early support for their groundbreaking work. With a focus on biotechnology, health care, and the pharmaceutical industry, Synlife is positioned to make a significant impact in the healthcare sector. While the company's headquarters information is not provided, the recent investment underscores the potential of their synthetic cell-based therapeutics.

Taxonomy: Synthetic Biology, Therapeutics, Metabolic Diseases, Diagnostic Platforms, Biochemical Engineering, Genetic Engineering, Synthetic Cells, DNA Program, Protein Engineering, Cell-Free Systems

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• - 27 Jul 2018

Synlife Alternatives & Competitors

Synlife vs
CB Therapeutics
CB Therapeutics United States

CB Therapeutics produces high value molecules, compounds and rare ingredients with novel, proprietar...

Series A
15 employees
Biotechnology, Health and Wellness
Synlife vs
DNA2.0 (now ATUM)
DNA2.0 (now ATUM) United States

This page is retired. You can find our new company page at www.linkedin.com/company/atum-bio

9 employees
Biotechnology
Synlife vs
GAIA BIO
GAIA BIO Israel

A first Synthetic Biology platform focused on environment and sustainability

6 employees
Biotechnology, ESG

FAQ About Synlife

Artificial cells as novel therapeutics.
Synlife was founded in 2017.
Synlife is headquartered in Cambridge, United States.
Synlife operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Synlife has approximately 3 employees.
Synlife has completed 1 funding round, raising a total of $700.00K. The latest funding stage is Seed.
Top alternatives and competitors to Synlife include CB Therapeutics, DNA2.0 (now ATUM), GAIA BIO, De Novo DNA, Think Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Synlife and CB Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Synlife and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy